What is the address of StratyPharma?

The registered office of StratyPharma is located at Franklin Rooseveltlaan 242 box 3, 1050 Brussel.

Is StratyPharma still active?

Yes. According to the CBE (31 October 2026) StratyPharma is active, legal situation “Normale toestand”, started on 11 June 2021.

Is StratyPharma registered on Peppol?

Yes, StratyPharma is registered on the Peppol network with ID 0208:0769613935.

What is the enterprise number of StratyPharma?

The enterprise number of StratyPharma is BE0769613935.

When was StratyPharma founded?

StratyPharma was founded on 11 June 2021.

Who are the directors of StratyPharma?

According to the 2025 annual accounts, the directors of StratyPharma are: Alexandre BERTRAND.

Is StratyPharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 June 2021; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did StratyPharma make in 2025?

StratyPharma posted a profit after taxes of € 55,327 in financial year 2025.

What is the revenue of StratyPharma?

As a small company, StratyPharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 67,544.

StratyPharma (Private Limited) - Brussel - BE0769613935

Q: What does StratyPharma do?

StratyPharma is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 11 June 2021, 1 establishment.

Dossier StratyPharma, printed on 1 November 2026 from databakkes.be/en/0769613935/stratypharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Figures corrected NBB

Corrected annual account filed for 2024.

Financials

Financial year 2025

StratyPharma from Brussel, company number BE0769613935, closed financial year 2025 with a result of € 55,327 after tax. For that financial year StratyPharma recorded a gross margin of € 67,544 and equity of € 227,483. Compared with financial year 2024, the result moved from € 44,098 to € 55,327. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 18, 2026.

What it is worth Growing

€ 227,483

▲ 32% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 55,327

▲ 25% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 28,844

▲ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 833 paid out

2 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 892

▼ 59% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 37

▲ € 31 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 8,667

▼ 56% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 76,525 Gross margin 2022: € 76,525 First fiscal year in the series	€ 88,589 Gross margin 2023: € 88,589 ▲ 16% vs 2022 (€ 76,525) Favourable step	€ 60,573 Gross margin 2024: € 60,573 ▼ 32% vs 2023 (€ 88,589) Unfavourable step	€ 67,544 Gross margin 2025: € 67,544 ▲ 12% vs 2024 (€ 60,573) Favourable step	▲ 12%
Profit after taxes	€ 53,263 Profit after taxes 2022: € 53,263 First fiscal year in the series	€ 62,093 Profit after taxes 2023: € 62,093 ▲ 17% vs 2022 (€ 53,263) Favourable step	€ 44,098 Profit after taxes 2024: € 44,098 ▼ 29% vs 2023 (€ 62,093) Unfavourable step	€ 55,327 Profit after taxes 2025: € 55,327 ▲ 25% vs 2024 (€ 44,098) Favourable step	▲ 25%
Equity	€ 68,489 Equity 2022: € 68,489 First fiscal year in the series	€ 129,749 Equity 2023: € 129,749 ▲ 89% vs 2022 (€ 68,489) Favourable step	€ 172,989 Equity 2024: € 172,989 ▲ 33% vs 2023 (€ 129,749) Favourable step	€ 227,483 Equity 2025: € 227,483 ▲ 32% vs 2024 (€ 172,989) Favourable step	▲ 32%
Total debts	€ 28,946 Total debts 2022: € 28,946 First fiscal year in the series	€ 35,990 Total debts 2023: € 35,990 ▲ 24% vs 2022 (€ 28,946) Unfavourable step	€ 25,580 Total debts 2024: € 25,580 ▼ 29% vs 2023 (€ 35,990) Favourable step	€ 15,049 Total debts 2025: € 15,049 ▼ 41% vs 2024 (€ 25,580) Favourable step	▼ 41%
Cash	€ 89,523 Cash 2022: € 89,523 First fiscal year in the series	€ 55,015 Cash 2023: € 55,015 ▼ 39% vs 2022 (€ 89,523) Unfavourable step	€ 23,350 Cash 2024: € 23,350 ▼ 58% vs 2023 (€ 55,015) Unfavourable step	€ 28,844 Cash 2025: € 28,844 ▲ 24% vs 2024 (€ 23,350) Favourable step	▲ 24%
Retained profit	€ 67,989 Retained profit 2022: € 67,989 First fiscal year in the series	€ 129,249 Retained profit 2023: € 129,249 ▲ 90% vs 2022 (€ 67,989) Favourable step	€ 172,489 Retained profit 2024: € 172,489 ▲ 33% vs 2023 (€ 129,249) Favourable step	€ 226,983 Retained profit 2025: € 226,983 ▲ 32% vs 2024 (€ 172,489) Favourable step	▲ 32%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 833 Dividend 2023: € 833 ▲ 4% vs 2022 (€ 800) Unchanged	€ 859 Dividend 2024: € 859 ▲ 3% vs 2023 (€ 833) Unchanged	€ 833 Dividend 2025: € 833 ▼ 3% vs 2024 (€ 859) Unchanged	▼ 3%
Balance sheet total	€ 97,435 Balance sheet total 2022: € 97,435 First fiscal year in the series	€ 165,739 Balance sheet total 2023: € 165,739 ▲ 70% vs 2022 (€ 97,435) Unchanged	€ 198,569 Balance sheet total 2024: € 198,569 ▲ 20% vs 2023 (€ 165,739) Unchanged	€ 242,532 Balance sheet total 2025: € 242,532 ▲ 22% vs 2024 (€ 198,569) Unchanged	▲ 22%

Key figures of StratyPharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to StratyPharma?

What happened at StratyPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 18, 2026 New annual accounts for financial year 2025: profit of € 55,327 (▲ 25% vs 2024). filed late Source: NBB ↗
Jun 11, 2021 New establishment in Brussel. KBO
2021 Alexandre BERTRAND became a director. NBB
Jun 11, 2021 Start of the company according to the CBE. KBO

In short

From € 53,263 profit in 2022 to € 55,327 profit in 2025.

Paid € 78,851 in corporate taxes since 2022.

Best year ever: 2023, with € 62,093 profit.

Paid out € 3,325 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Alexandre BERTRAND

StratyPharma

Behind StratyPharma is Alexandre BERTRAND.

Directors

According to the 2025 annual accounts

Alexandre BERTRAND

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Franklin Rooseveltlaan 242 box 3

1050 Brussel

2.318.123.816

Franklin Rooseveltlaan 242

1050 Brussel

Active since 11 June 2021

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.

All companies at this address →

SG SPORTS CONSULTANCE

PLEIAD

€ 58,654 gross margin · 2025

ARCHITECTES 3 DEVELOPMENT

€ 256,824 gross margin · 2025

A.C.P. AV FR.ROOSEVELT 242 244 1050 BRUXELLES

A3 FABRICS

€ 953 gross margin · 2025

+2 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0769.613.935

VAT number

BE 0769.613.935

Registered office

Franklin Rooseveltlaan 242 bus 3, 1050 Brussel

Names & denominations

StratyPharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

11 June 2021

Peppol

Active · Active since 17 Sept 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

StratyPharma

Warning lights

Financials

What happened to StratyPharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions